Compare Research Peptides

Select 2 peptides to compare benefits, dosage, administration routes, mechanisms, and side effect profiles side by side.

Peptide 1

Peptide 2

	MOTS-c Mitochondrial ORF of the 12S rRNA-c Sign up to track	Exenatide Byetta Sign up to track
Evidence Grade	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved
Regulatory	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only	FDA ApprovedFDA ApprovedApproved by the US Food and Drug Administration for at least one indication
Category	Metabolic & Weight Loss	Metabolic & Weight Loss
Key Benefits	•Improves insulin sensitivity •Enhances exercise capacity and endurance •Metabolic regulation and longevity •Increases NAD+ levels +3 more	•Improves glycemic control •Promotes weight loss •Slows gastric emptying •Reduces HbA1c by 0.8-1.5% +2 more
Dosage	5-10 mg mg	5-10 mcg (twice daily) or 2 mg (weekly) mcg
Frequency	2-3x per week	Twice daily or once weekly
Administration	SubcutaneousIntramuscular	Subcutaneous
Mechanism	MOTS-c is a mitochondrial-derived peptide that acts as a mitochondrial signaling molecule. It regulates metabolic homeostasis and has been called an 'exercise mimetic' due to its effects on metabolism and exercise capacity.	Exenatide is the first GLP-1 receptor agonist approved by the FDA. Based on exendin-4 from Gila monster saliva, it is available as twice-daily or once-weekly formulation for type 2 diabetes and weight management.
Side Effects / Risks	Not specified	Not specified
Research Status	Research compound with growing scientific interest	FDA-approved for type 2 diabetes